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Background: Health Related Quality of Life (HRQOL) is impaired in hemodialysis patients and cardiac biomarkers
are elevated, but their relationship is uncertain.
Objectives: To determine whether the cardiac biomarkers, troponin T and N terminal pro-B type natriuretic peptide
(NT-proBNP), predict deterioration in the physical domains of HRQOL.
Design: A prospective cohort study of patients in a randomized controlled clinical trial of correction of anemia with
erythropoietin.
Setting: Multiple hemodialysis centers located throughout Canada and Europe.
Participants: Patients who started maintenance hemodialysis within the previous 3–18 months, with no clinical
evidence or prior history of symptomatic cardiac failure or ischemic heart disease, and left ventricular volume
< 100 ml/m2.
Measurements: Predictor: Baseline concentrations of Troponin T and NT-proBNP. Outcomes: Physical function and
vitality scores using the SF-36 questionnaire and fatigue scores using the FACIT questionnaire at baseline and after
24, 48, and 96 weeks follow-up.
Methods: Univariate analysis of the association between baseline variables and baseline HRQOL scores and change
in scores over time was undertaken using linear regression. Multivariate models were created using multiple linear
regression, and it was pre-specified that these include the variables which were associated with the outcome at a
p < 0.05 in the univariate regression.
Results: Baseline median (interquartile range) physical function score was 70 (50–85), vitality 55 (40–75), and fatigue
73 (58–86). The 75th percentile for Troponin T was 0.05 ng/mL and for NT-proBNP 652 ng/mL. High Troponin T
levels were significantly associated with deterioration in the 3 physical domains, independent of other risk factors,
whereas high NT-proBNP were not associated. In multivariate models baseline Troponin T > 0.05 ng/mL were
significantly associated with the change from baseline to 96 weeks follow-up for SF-36 vitality and FACIT-fatigue
scores, and approached statistical significance for SF-36 physical function (0.056).
Limitations: Not possible to confirm whether Troponin T associations were independent of subsequent cardiac
events.
Conclusions: In hemodialysis patients without prior symptomatic cardiac disease and without a dilated left
ventricle at baseline, elevated baseline Troponin T levels, but not NT-pro BNP, were independently associated with
deterioration in the physical domains of HRQOL.* Correspondence: pparfrey@mun.ca
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Contexte: Chez les patients en hémodialyse, la qualité de vie liée à la santé (QVLS) est diminuée, et les biomarqueurs
cardiaques sont élevés, mais la relation entre les deux est incertaine.
Objectifs: Déterminer si les biomarquers cardiaques, la troponine T et le N-terminal peptide natriurétique de type B
(NT-ProBNP), prédisent la détérioration des domaines physiques de la QVLS.
Type d’étude: Une étude prospective de cohorte sur des patients dans le cadre d’un essai clinique contrôlé
randomisé concernant la correction de l’anémie à l’aide de l’érythropoïétine.
Contexte: Plusieurs centres d’hémodialyse situés au Canada et en Europe, coordonnés de façon centralisée à partir de
St. John’s, au Canada, pour les patients canadiens, et de Manchester, en Angleterre, pour les patients européens.
Participants: Les patients en hémodialyse chronique de plusieurs centres, qui ont entamé une dialyse au cours des
derniers 3 à 18 mois, et qui ne présentent aucune donnée clinique et aucun antécédent d’insuffisance cardiaque
symptomatique ou de cardiopathie ischémique, mais un volume ventriculaire gauche < 100 ml/m2.
Mesures: Prédicteur: concentration de référence de Troponine T et de NT-proBNP. Résultats: Degré de vitalité et
fonction physique à l’aide du questionnaire SF-36 et degré de fatigue à l’aide du questionnaire FACIT, au point de
référence, puis après le suivi des 24, 48 et 96 semaines.
Méthodes: L’analyse unidimensionnelle de l’association entre les variables fondamentales et les scores de référence de
la QVLS, et la variation dans les scores a été entreprise au moyen de la régression linéaire. Les modèles multivariables
ont été créés en utilisant la régression linéaire multiple, et il a été pré-spécifié que ceux-ci comprenaient les variables
associées aux résultats de p < 0,05 dans la régression à une variable.
Résultats: Le score médian de référence (écart interquartile) de la fonction physique était de 70 (50–85), celui de la
vitalité de 55 (40–75), et celui de la fatigue 73 (58–86). Le 75e percentile de la troponine T était de 0,05 ng/mL, et pour
le NT-proBNP, de 652 ng/mL. Les niveaux élevés de troponine T étaient associés de façon significative à la détérioration
des 3 domaines physiques, indépendants des autres facteurs de risque, alors que les niveaux élevés de NT-proBNP ne
démontraient aucune association significative. Dans les modèles multivariables, un niveau fondamental de troponine T
> 0,05 ng/mL était associé de façon significative à la variation entre le point de référence et le suivi des 96 semaines en
ce qui a trait aux scores SF-36 de vitalité et FACIT de fatigue, et avaient une certaine signification statistique à une
fonction physique de SF-36 (0,056).
Limites de l’étude: Impossible de confirmer si les associations avec la troponine T étaient indépendantes
d’événements cardiaques subséquents.
Conclusions: Chez les patients en hémodialyse ne présentant pas d’antécédents de maladie cardiaque symptomatique
ni une dilatation du ventricule gauche au point de référence, des niveaux élevés de troponine T au point de référence,
mais pas de NT-proBNP, ont été indépendamment associés à une détérioration des domaines physiques de QVLS.
Trial registration: Clinical trials.gov # NCT00261521.What was known before
Patients with ESRD have diminished scores in the phys-
ical domains of health related quality of life. Biomarkers
for adequacy of dialysis, mineral metabolism and inflam-
mation correlate poorly with these domains, although
nutritional biomarkers do correlate.
What the study adds
In hemodialysis patients without prior symptomatic car-
diac disease elevated baseline Troponin T levels, but not
B type natriuretic peptide, are associated with deterior-
ation in the physical domains of quality of life.
Background
Health Related Quality of Life (HRQOL) is a consistent
predictor of mortality in end stage renal disease (ESRD)(1-3). Patients with ESRD have consistently diminished
HRQOL compared with matched controls without ESRD,
most pronounced in physical function and vitality (4). Bio-
markers are regularly tracked in dialysis units, but
biomarkers for adequacy of dialysis (KT/V), mineral me-
tabolism and inflammation correlate poorly with HRQOL,
although nutritional biomarkers associate with the phys-
ical domains in HRQOL (4). Although HRQOL scores are
substantially higher in hemodialysis (HD) patients without
prior symptomatic cardiac disease compared to unselected
hemodialysis patients (5,6) the relationship between car-
diac biomarkers, such as N terminal pro-B type naturetic
peptide (NT-proBNP) and troponin T, and HRQOL is
uncertain.
Cardiovascular events, particularly heart failure and
atherosclerotic events have a major impact on HRQOL
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enced these events may have elevated troponin T, a
marker of myocardial injury, or elevated NT-proBNP, a
marker of left ventricular (LV) wall stress (8). To deter-
mine whether these cardiac biomarkers associate with
poor HRQOL or predict deterioration in HRQOL we an-
alyzed troponin T and NT-proBNP levels in incident HD
patients, without prior cardiac failure or ischemic heart
disease events and without overt cardiac dilation (N =
596), followed for 2 years in a multinational, blinded,
randomized controlled trial (8,9), in whom HRQOL was
measured at baseline and serially during follow-up using
the SF-36 and FACIT fatigue questionnaires (5).
We hypothesized that cardiac biomarkers would pre-
dict deterioration in the physical domains of HRQOL,
independent of other baseline clinical characteristics.
The objectives of this report are to quantify the associa-
tions between traditional biomarkers and cardiac bio-
markers, measured at baseline in incident HD patients
without symptomatic cardiac disease, and baseline mea-
sures of physical function, vitality, and fatigue, together
with short-term (24 weeks) and long-term (1 and 2 years)
changes in these domains.
Methods
The cohort studied in this paper was enrolled in a ran-
domized trial of correction of anemia with erythropoietin
(9). The design, methods, randomization, and epoetin dos-
ing protocols have been reported previously (9). Patients
were randomly assigned to one of the following hemo-
globin (Hb) targets: 9.5 to 11.5 (low target) or 13.5 to
14.5 g/dl (high target). Patients were masked to treatment
assignment, as were their doctors. Mean Hb levels at the
end of the initial 24-week titration phase were 13.3 and
10.9 g/dl, respectively. During the maintenance phase,
from weeks 24 through 96, corresponding mean Hb levels
were 13.1 and 10.8 g/dl. Cardiac structure constituted the
primary study outcome, and no difference was observed
between the two groups (9). Consequently, for the pur-
pose of this article, all patients were included as one co-
hort. The study was centrally coordinated from St. John’s,
Canada, for Canadian patients and Manchester, England,
For European patients.
Local independent ethics committees or institutional
review boards approved the study protocol form before
study initiation. The study was conducted in accordance
with Good Clinical Practice guidelines and the Declar-
ation of Helsinki. All patients gave informed consent be-
fore study enrollment.
Study population
Inclusion criteria were as follows: Age ≥ 18 years; incep-
tion of maintenance HD within the previous 3 to
18 months; predialysis Hb level between 8 and 12 g/dl;LV volume index (LVVI) < 100 ml/m2, and predialysis
diastolic BP (DBP) < 100 mmHg. Exclusion criteria were
as follows: Clinical evidence or history of symptomatic
cardiac failure or ischemic heart disease; daily prednis-
one dosages ≥ 10 mg; medical conditions that are likely
to reduce epoetin responsiveness, including uncorrected
iron deficiency; concurrent malignancy; blood transfusion
in the preceding month; therapy with cytotoxic agents;
seizure in the preceding year; hypersensitivity to intraven-
ous iron; and current pregnancy or breastfeeding.
Description of study procedures
Laboratory tests were measured centrally by Quest Diag-
nostics (Van Nuys, CA, and Heston, UK). With the high
target, the treatment goal was increments of 0.5 to
1.0 g/dl every 2 weeks, until achieving stability between
13.5 and 14.5 g/dl. Other treatment goals included
predialysis diastolic blood pressure between 70 and
90 mmHg, urea reduction ratio > 67%, and transferrin
saturation ≥ 20%. On a weekly basis, midweek predialysis
blood pressure levels were communicated weekly to and
treatment recommendations sent from the coordinating
center. These were determined by the protocols in use
at the individual treating centers, and a single, formal,
standardized method was not imposed. The last patient
completed the study in May 2003.
Quality of life was assessed using the KDQOL and
FACIT fatigue questionnaires (10,11). We pre-specified
the domains of HRQOL for this analysis: physical func-
tion and vitality measured using the SF-36 questionnaire
and fatigue using the FACIT fatigue questionnaire.
Higher scores reflect better health. These were also the
pre-specified domains for HRQOL outcomes in the trial
(5). A-priori we defined short-term change in HRQOL
as the change from baseline to the assessment at
24 weeks, and long-term change as the change from
baseline to the assessments made at 48 and 96 weeks.
There was no difference in the clinical or demographic
characteristics or in treatment assignment of those who
had only one KDQOL assessment n = (12) and those
who had serial assessments (n = 484). At each assess-
ment, > 90% of patients remaining in the study com-
pleted the questionnaire.
Sample size estimate
The sample size needed to detect a 15% difference be-
tween treatment groups in the primary outcome (left
ventricular cavity volume index) was calculated as 166
per treatment group, given a two-tailed significance of
0.05, a power of 0.90, and an SD of the percentage
change in left ventricular cavity volume index of 42%
(9). With an expected dropout rate of 40%, primarily as
a result of transplantation, 277 patients were required
for each treatment group.
Table 1 Baseline demographic and clinical characteristics,
biomarkers and HRQOL scores
Age (yrs); median (25th to 75th percentiles) 51.5 (39 to 62)
Female; N (%) 236 (39.6)
Non-white race; N (%) 63 (10.6)
Cause of ESRD:
Glomerulonephritis; N (%) 171 (28.7)
Diabetic Nephropathy; N (%) 106 (17.8)
Polycistic kidney disease; N (%) 54 (9.1)
Hypertension; N (%) 48 (8.1)
Other/Unknown; N (%) 217 (36.4)
Dialysis duration (mo); median
(25th to 75th percentiles)
9 (6 to 14)
Dialysis access:
Fistula; N (%) 502 (84.2)
Graft; N (%) 33 (5.5)
Catheter; N (%) 61 (10.2)
Assigned to high Hb target; N (%) 296 (49.7)
Epoetin dosage (U/wk); median
(25th to 75th percentiles); n = 584
6000 (4000 to 8000)
BMI (kg/m2); median (25th to 75th percentiles) 25.5 (22.6 to 29.3)
Systolic BP (mmHg); median
(25th to 75th percentiles); n = 595
140 (130 to 158)
Diastolic BP (mmHg); median
(25th to 75th percentiles); n = 596
80 (71 to 90)
Hemoglobin (g/dl); median
(25th to 75th percentiles); n = 580
11 (10.2 to 11.7)
Serum albumin (g/L); median
(25th to 75th percentiles); n = 588
40 (38 to 41)
Urea reduction ratio (%); median
(25th to 75th percentiles); n = 572
67 (60 to 72.5)
Biomarkers; median (25th to 75th percentiles)
Cardiac: Troponin T (ng/ml); n = 481 0.021 (0.009 to 0.051)
NT-proBNP (pg/ml); n = 481 289.2 (137.3 to 651.9)
Inflammatory: C-Reactive protein (mg/L); n = 481 3.47 (1.47 to 8.13)
IL-6 (pg/ml); n = 481 4.39 (2.69 to 8.8)
Leptin (ng/ml); n = 481 12.4 (3.7 to 43.8)
Quality of life domains; median
(25th to 75th percentiles)
SF-36 Physical functioning; n = 457 70 (50 to 85)
SF-36 Vitality; n = 457 55 (40 to 75)
FACIT Fatigue; n = 572 73.1 (57.7 to 86.3)
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FACIT fatigue in 572 patients. The comparable numbers
at 24 weeks were 443 and 499, at 48 weeks 435 and 432,
and at 96 weeks 335 and 325.
Risk factors
In addition to demographic factors (age, gender, and
race), baseline clinical characteristics (diabetes, primary
renal disease, dialysis vintage, blood pressure, body mass
index, type of vascular access) were recorded, as were
conventional laboratory tests results (Hb, white cell
count, percentage of iron saturation, urea reduction ra-
tio, and serum albumin) and other serologic tests at
baseline. Serum concentrations of N terminal pro-B type
natriuretic peptide (NT-proBNP) and cardiac troponin T
were measured in 2009 using diagnostic kits and per-
formed on an Elecsys 2010 immunochemistry analyzer
(Roche Diagnostics, Montreal, Quebec, Canada). Serum
high-sensitivity C-reactive protein was measured using
CRP reagent (Beckman Coulter, Fullerton, CA) and per-
formed on an IMMAGE Immunochemistry system
(Beckman Coulter). Serum IL-6 was measured using IL-
6 kits and performed on a Unicel DxI 800 Access Im-
munoassay system (Beckman Coulter). Serum leptin was
measured by ELISA technique using kits purchased from
Diagnostic Systems Laboratories, Inc (Webster, Tx).
Statistical analysis
Baseline characteristics were described by number (%) or
by median with interquartile range. For the cardiac and in-
flammatory biomarkers high levels were pre-specified as
above the 75th percentile. Univariate analysis of the asso-
ciation between baseline variables and baseline HRQOL
scores and change in scores over time was undertaken
using linear regression. Multivariate models were created
using multiple linear regression, and it was pre-specified
that these include the variables which were associated
with the outcome at a p < 0.05 in the univariate regression.
In addition multivariate models were created to determine
the effect of troponin T levels on change in HRQOL inde-
pendent of age, sex, diabetes and baseline HRQOL score.
Results
A total of 596 patients were enrolled in 95 treatment cen-
ters in 10 countries between February 2000 and June
2001. Table 1 shows baseline characteristics. Median age
was 51.5 years, 39.6% were female, and the vast majority
were white. Only 17.8% had diabetes as the cause of
ESRD, and patients with a clinical history of cardiac failure
and ischemic heart disease were excluded. Incident pa-
tients who started dialysis between 3 and 18 months be-
fore study entry were enrolled, and median time on
dialysis was 9 months. The vast majority (84.2%) had a fis-
tula as vascular access. The distribution of troponin T andfor NT-proBNP at baseline is displayed in Figure 1 A and
B. The upper quartile for troponin T was > 0.051 ng/ml
(N = 118), and for NT-proBNP it was > 652 pg/ml (N= 120).
Serial HRQOL scores
Median score for SF-36 physical function was 70, for SF-
36 vitality it was 55, and for FACIT fatigue 73 (Table 1).
Figure 1 Distribution of baseline troponin T levels (A) and NT-proBNP (B) levels in hemodialysis patients without prior symptomatic
cardiac disease. Troponin T levels are expressed in units of ng/mL and NT-proBNP in units of pg/mL).
Williams et al. Canadian Journal of Kidney Health and Disease 2014, 1:16 Page 5 of 10
http://www.cjkhd.org/content/1/1/16Figure 2 shows the median scores at baseline, 24, 48,
and 96 weeks for the cohort.
Associations with baseline HRQOL scores
Table 2 shows the significant univariate associations be-
tween baseline clinical variables and biomarkers withHRQOL scores. Multivariate models revealed that the
significant, independent variables associated with better
SF-36 physical function were younger age, presence of a
fistula, and lower NT-proBNP. For higher SF-36 vitality
and FACIT fatigue scores only higher URR was identi-
fied as a significant predictor (Table 2). Additional file 1:
Figure 2 Serial HRQOL scores for SF-36 domains physical function and vitality, and for FACIT fatigue, in hemodialysis patients without
symptomatic cardiac disease.
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domains, which were not pre-specified.
Associations with change in HRQOL
Table 3 shows the significant univariate and multivariate
associations for both short-term (24 weeks) and long-term
(48 and 96 weeks) change in HRQOL for the 3 domains
of interest. High troponin T levels at baseline were signifi-
cantly and independently associated with decrease in SF-
36 physical function at 48 weeks, decrease in SF-36 vitality
at 96 weeks and decrease in FACIT fatigue at 24 weeks,
independent of other variables significantly associated
with the outcome. In a second multivariate model high
troponin T levels were significantly associated with deteri-
oration in physical function at 24, 48, and 96 weeks, de-
crease in vitality at 96 weeks, and decrease in fatigue at
24 weeks, independent of age, sex, diabetes and baseline
HRQOL score (Table 4). Examination of the unadjusted
and adjusted B coefficients (Table 4) suggest consistent
impact of baseline troponin T levels on change in
HRQOL. General linear models for repeated measures
demonstrated that high troponin T levels were signifi-
cantly associated with decrease in physical function scores
(p < 0.001), decrease in vitality of borderline significance
(p = 0.06), decrease in fatigue scores (p = 0.04).
Baseline NT-proBNP levels were not predictive of
change in HRQOL (Additional file 1: Table S2), nor were
biomarkers of inflammation (CRP and ILS) or leptin.
Additional file 1: Table S3 shows the results from ana-
lysis of the other SF-36 domains, which were not pre-
specified.Clinical associations with baseline Troponin T
Table 5 shows the significant univariate and multivariate
associations between high troponin T levels at baseline
and baseline clinical characteristics and biomarkers. The
independent and significant predictors of high levels
were male sex, older age, diabetes, high lactic dehydro-
genase and high NT-proBNP levels.
Discussion
The major conclusions in this paper were that in new
hemodialysis patients without symptomatic cardiac disease:
1) HRQOL scores for physical function, vitality and
fatigue were closer to those for the general
population than for unselected hemodialysis
patients, and on average changed little over 2 years
of follow-up.
2) troponin T levels were elevated at baseline in a
substantial minority of patients, and high values
were significantly associated with high NT-proBNP
levels independent of age, sex and diabetes.
3) high troponin T levels at baseline were significantly
associated with decrease in physical function, vitality
and fatigue, whereas NT pro-BNP levels were not.
The mean score in the general population for SF-36
physical function was 86 and for dialysis patients 41,
(12,6), whereas in our patients without symptomatic car-
diac disease the score was 67 (5). For SF-36 vitality the
comparable scores were 66, 43 and 58, and for FACIT
fatigue the mean score in the general population was 80,
Table 2 Significant associations between baseline clinical variables and biomarkers and baseline HRQOL scores, using
univariate and multivariate analysis
Characteristic Reference Unadjusted B
coefficient
95% C.I. Adjusted B
coefficient
95% C.I.
SF-36 Physical functioning
Female Male −7.56 −12.30 to −2.81**
Age Per 1 year −0.49 −0.63 to −0.35** −0.38 −0.56 to −0.20**
Body Mass Index Per 1 kg/m2 −0.63 −1.05 to −0.20**
Diabetes No Diabetes −8.25 −14.27 to −2.23**
Fistula No Fistula 12.52 6.54 to 18.51** 10.69 3.52 to 17.86**
Serum Albumin ≤ 40 g/L 6.36 1.54 to 11.18**
Serum Creatinine Per 1 umol/L 0.02 0.01 to 0.03**
Sodium Per 1 mmol/L 0.76 0.06 to 1.46*
White Blood Cells ≤ 8.1 × 109/L −7.98 −13.60 to −2.37**
Neutrophils ≤ 68% −7.33 −12.90 to −1.77**
Leptin Per 1 ng/ml −0.17 −0.26 to −0.08**
Troponin T ≤ 0.05 ng/ml −9.54 −15.60 to −3.48**
NT-proBNP ≤ 651.9 pg/ml −6.05 −12.11 to 0.01* −6.33 −12.40 to −0.26*
IL-6 Per 1 pg/ml −0.19 −0.38 to −0.01*
SF-36 Vitality
Female Male −5.73 −9.88 to −1.58**
Urea Reduction Ratio ≤ 60% 8.58 3.52 to 13.64** 6.33 0.48 to 12.17*
White Blood Cells ≤ 8.1 × 109/L −6.76 −11.62 to −1.91**
Leptin Per 1 ng/ml −0.09 −1.17 to −0.01*
C-reactive protein Per 1 mg/L −0.18 −0.35 to −0.00*
FACIT Fatigue
Female Male −5.00 −8.26 to −1.73**
Body Mass Index Per 1 kg/m2 −0.30 −0.60 to 0.00*
Diabetes No Diabetes −5.07 −9.40 to −0.73*
Urea Reduction Rate ≤ 60% 6.75 3.04 to 10.47** 5.61 1.42 to 9.81**
Leptin Per 1 ng/ml −0.10 −0.17 to −0.04**
*p ≤ 0.05; **p ≤ 0.01.
Unadjusted B coefficient was calculated using univariate linear regression (column 3 and 4).
Adjusted B coefficient was calculated using multiple linear regression to identify the significant and independent predictors (column 5 and 6).
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Clearly the presence of symptomatic cardiac disease is
associated with HRQOL in dialysis patients. The current
paper demonstrates that in dialysis patients without
symptomatic cardiac disease at baseline few biomarkers
were consistently associated with the deterioration in
quality of life scores, but cardiac damage revealed by
high Troponin T levels was associated with deterior-
ation. It is important to note that the associations be-
tween change in HRQOL scores and high troponin T
levels were not confounded by the prior occurrence of
symptomatic heart failure or ischemic heart disease, or
by the presence of LV dysfunction defined by a high LV
volume. The fact that this group was relatively healthy is
confirmed by the observation of an annual mortality of5%, substantially lower than that in unselected hemo-
dialysis patients (9).
In the study by Apple et al. (14) using the 99th percent-
ile of a healthy reference population to define an elevated
troponin T level, 82% of unselected asymptomatic hemo-
dialysis patients had a level above this value ( > 0.01 ng/ml).
In our study the interquartile range was 0.01 to
0.05 ng/ml. It is likely that elevated troponin T levels in
dialysis patients reflects not only myocardial injury and is-
chemia but also myocardial fibrosis (15). A meta-analysis
suggested that an elevated troponin T > 0.1 ng/ml can
identify a subgroup of dialysis patients with poor survival
and higher risk of death (16). In a previous paper we re-
ported that higher troponin T levels were predictive of
subsequent cardiovascular events or death in our selected
Table 3 Significant associations between baseline clinical variables and biomarkers and change in short-term and
long-term HRQOL scores, using univariate and multivariate analysis
Characteristic Reference Unadjusted B
coefficient
95% C.I. Adjusted B
coefficient
95% C.I.
SF-36 Vitality
Change at 24 wks
High Hb Group Low Hb Group 5.09 1.16 to 9.03* 5.11 1.07 to 9.14*
Platelet Count ≤ 260 × 109/L −5.00 −9.63 to −0.38* −4.99 −9.58 to −0.40*
Change at 48 wks
Urea reduction ratio ≤ 60% −6.97 −12.22 to −1.72** −7.06 −12.35 to 1.77**
Serum calcium ≤ 2.42 mmol/L 5.34 0.94 to 9.73* 6.18 1.62 to 10.74**
Platelet count ≤ 260 × 109/L −5.93 −10.67 to −1.18* −5.01 −9.84 to −0.18*
Epo dose ≤ 6000 U/wk 5.25 1.07 to 9.43* 5.73 1.53 to 9.93**
Change at 96 wks
Fractional shortening Per 1% −0.32 −0.62 to −0.02*
Troponin T ≤ 0.051 ng/ml −7.55 −14.18 to −0.91* −7.09 −13.73 to −0.46*
SF-36 Physical functioning
Change at 24 wks
Left Ventricular Mass Index Per 1 g/m2 −0.06 −0.12 to −0.00*
Serum Calcium ≤ 2.42 mmol/L 4.25 0.02 to 8.47*
Platelet Count ≤ 260 × 109/L −5.54 −9.95 to −1/13 −5.93 −10.37 to −1.50**
Change at 48 wks
Serum Calcium ≤ 2.42 mmol/L 6.63 1.61 to 11.66** 6.00 0.39 to 11.62*
Troponin T ≤ 0.051 ng/ml −6.40 −12.62 to −0.18* −6.70 −12.93 to −0.47*
Change at 96 wks
Diabetes No Diabetes −7.28 −14.07 to −0.49* −8.84 −16.61 to −1.07*
Troponin T ≤ 0.051 ng/ml −9.43 −16.44 to −2.42**
FACIT Fatigue
Change at 24 wks
Lactase dehydrogenase Per 1 U/L −0.05 −0.09 to −0.00*
White blood cells ≤ 8.1 × 109/L −4.32 −8.19 to −0.46*
Troponin T ≤ 0.051 ng/ml −5.38 −9.37 to −1.38** −4.91 −9.09 to −0.74*
Change at 48 wks
Serum creatinine Per 1 umol/L 0.01 0.00 to 0.02** 0.01 0.00 to 0.02*
Platelet Count ≤ 260 × 109/L −5.06 −9.20 to −0.93* −4.78 −8.92 to −0.63*
Change at 96 wks
Epo Dose ≤ 6000 U/wk −5.11 −9.92 to −0.31*
*p ≤ 0.05; **p ≤ 0.01.
Unadjusted B coefficient was calculated using univariate linear regression (column 3 and 4).
Adjusted B coefficient was calculated using multiple linear regression to identify the significant and independent predictors (column 5 and 6).
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age, diabetes, systolic blood pressure or NT-proBNP levels
(8). The current paper lends support to the belief that high
troponin levels are not innocuous, and that they are asso-
ciated with deterioration in the physical domains of
HRQOL. Whether this effect is mediated via the develop-
ment of subsequent cardiac events which cause a decrease
in HRQOL or by the degree of myocardial injury presentat baseline is difficult to determine. The fact that high
Troponin T levels were associated with lower HRQOL
scores at baseline and after short-term follow-up suggests
that the latter hypothesis is tenable, particularly as only
4% of cases developed a cardiovascular/death event by six
months (myocardial infarction, myocardial ischemia, angina
pectoris, cardiac failure, pulmonary edema, cerebellar in-
farction, cerebral hemorrhage, cerebral vascular disorder, or
Table 4 The unadjusted and adjusted B coefficients for baseline Troponin T levels and baseline HRQOL scores and
change in these scores over time, using univariate and multivariate analysis
Unadjusted B p value Adjusted B* p value* Adjusted B** p value**
SF-36 Physical functioning
Baseline −9.54 0.002 −5.92 0.071
Change at 24 wks −4.13 0.111 −6.02 0.018
Change at 48 wks −6.40 0.044 −6.70 0.035 −8.09 0.008
Change at 96 wks −9.43 0.009 −7.60 0.056 −8.42 0.015
SF-36 Vitality
Baseline −1.56 0.571
Change at 24 wks −3.46 0.182 −3.23 NS
Change at 48 wks −1.36 0.633 −1.36 NS
Change at 96 wks −7.55 0.026 −7.09 0.036 −7.10 0.037
FACIT Fatigue
Baseline −1.58 0.465
Change at 24 wks −5.38 0.008 −4.91 0.021 −5.95 0.002
Change at 48 wks −3.89 0.093 −4.22 NS
Change at 96 wks −5.46 0.057 −6.19 0.035 −4.56 NS
*Adjusted for other variables with p ≤ 0.05.
**Adjusted for age, sex, diabetes status and baseline QoL score.
Unadjusted B coefficient was calculated using univariate linear regression.
Adjusted B coefficient was calculated using multivariate linear regression.
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http://www.cjkhd.org/content/1/1/16death) (8). Whether this interpretation is correct requires
further investigation.
BNP or NT-proBNP is a cardiac biomarker reflecting
LV wall stress that may occur secondary to volume ex-
pansion, pressure overload and increased wall tension
(15). In our previous paper NT-proBNP in this selected
group was an independent predictor of baseline LVMI,
of increase in LVMI over time, and of the subsequent
occurrence of cardiovascular events or death (8). Al-
though higher BNP levels may be associated with leftTable 5 Significant associations between baseline Troponin T l
and multivariate analysis
Characteristic Reference Unadjusted B
coefficient
Sex Male 0.52
Age Per 1 year 1.03
Diabetes No Diabetes 4.59
LV Mass Index 1 g/m2 1.01
Hb ≤ 11.1 g/dL 0.52
Serum Albumin ≤ 40 g/L 0.56
Lactate Dehydrogenase 1 U/L 1.015
Potassium 1 mmol/L 1.36
White Blood Cells ≤ 8.1 × 109/L 1.84
Platelet Count ≤ 260 × 109/L 1.73
NT-proBNP ≤ 651.9 pg/ml 4.00
*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.
Unadjusted B coefficient was calculated using univariate linear regression (column
Adjusted B coefficient was calculated using multivariate linear regression to identifyventricular hypertrophy and with systolic dysfunction, in
stable hemodialysis patients with normal LV function on
echocardiography high BNP levels are likely the result of
blood volume expansion and decrease with reduction in
post dialysis “dry” weight (17). In the current paper, high
BNP levels were not associated with a decrease HRQOL
in the short-term or the long-term.
Limitations of the study include: 1. the study from
which the data originated was not designed to evaluate
the impact of cardiac biomarkers on HRQOL. 2. It wasevels and baseline clinical characteristics, using univariate
95% C.I. Adjusted B
coefficient
95% C.I.
0.33 to 0.82** 0.38 0.22 to 0.67***
1.01 to 1.04** 1.02 1.00 to 1.04*
2.81 to 7.48*** 4.62 2.55 to 8.38***
1.01 to 1.02***
0.33 to 0.80**
0.36 to 0.88*
1.01 to 1.02*** 1.01 1.00 to 1.02*
1.03 to 1.79*
1.15 to 2.95*
1.09 to 2.75*
2.55 to 6.28*** 3.53 2.04 to 6.13***
3 and 4).
the significant and independent predictors (column 5 and 6).
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were predictive of HRQOL independent of subsequent
cardiac events. However the group studied limited con-
founding induced by the presence of symptomatic cardiac
disease and of echocardiographic systolic dysfunction. 3. It
is possible that patients who did not have repeat measure-
ments of HRQOL may be systematically different but this
would likely lead to underestimate of the true association
between the biomarkers and HRQOL.
Conclusion
We conclude that in a group of patients without prior
symptomatic cardiac disease at baseline or without a di-
lated LV, elevated troponin T levels, but not elevated
BNP levels, on starting hemodialysis are associated with
deterioration in the physical domains of HRQOL.
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